Funding for this research was provided by:
Associazione Italiana per la Ricerca sul Cancro (ig19991)
Fondazione Cassa di Risparmio di Padova e Rovigo (SIGMI)
Ministero dell’Istruzione, dell’Università e della Ricerca (2017BF3PXZ)
Received: 31 October 2021
Accepted: 26 February 2022
First Online: 12 March 2022
: All in vivo experiments were approved by the local Animal Ethic Commission (File number 2166, “Commission d’éthique de l’utilisation des animaux de l’Université de Liège”).
: Not applicable.
: LS is an inventor in the PCT/EP2019/068846 on MYLS22 as an anticancer drug. All other authors declare no competing interest.